The concept that prostein IHC can be used to corroborate a suspected prostatic origin of a cancer tissue is further supported by the retained prostein expression in at least 80% of prostate cancers that recurred after hormonal therapy [19]. Here, SLC45A3 is linked to Familial prostate cancer.